Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor. - Wikidata - wikimedia - TriplyDB

Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor.

Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor.

http://www.wikidata.org/entity/Q38309810

about

Aptamers: A Feasible Technology in Cancer Immunotherapy From selection hits to clinical leads: progress in aptamer discovery Aptamers: A promising chemical antibody for cancer therapy Generation of Aptamers with an Expanded Chemical Repertoire Nucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical Sensing Crystal Structure of Interleukin-6 in Complex with a Modified Nucleic Acid Ligand Antibody- and aptamer-strategies for GvHD prevention.Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy The Toolbox for Modified Aptamers.In vitro selection technologies to enhance biomaterial functionality.DNA display of folded RNA libraries enabling RNA-SELEX without reverse transcription.Chemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys.DNA-Catalyzed Amide Hydrolysis Selection of DNA aptamers with two modified bases.Analysis of ATP and AMP binding to a DNA aptamer and its imidazole-tethered derivatives by surface plasmon resonance.Trends in aptamer selection methods and applications.Status and Prospects of Aptamers as Drug Components.Immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics.Aptamers Against Pro- and Anti-Inflammatory Cytokines: A Review.An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid A secretion in vivo.Recent Advances in Aptamers Targeting Immune System.Influence of 5-N-carboxamide modifications on the thermodynamic stability of oligonucleotides.Chemical Modifications of Nucleic Acid Aptamers for Therapeutic Purposes.Nucleobase modification by an RNA enzyme.A Novel PEGylation Method for Improving the Pharmacokinetic Properties of Anti-Interleukin-17A RNA Aptamers.Nucleic Acid Aptamers: Emerging Applications in Medical Imaging, Nanotechnology, Neurosciences, and Drug Delivery.Pharmacokinetic Properties of DNA Aptamers with Base Modifications.Chemical modification improves the stability of the DNA aptamer GBI-10 and its affinity towards tenascin-C.Key Aspects of Nucleic Acid Library Design for in Vitro Selection.Molecular modeling and SPRi investigations of interleukin 6 (IL6) protein and DNA aptamers.Crystal structures of thrombin in complex with chemically modified thrombin DNA aptamers reveal the origins of enhanced affinity.Evolution of sequence-defined highly functionalized nucleic acid polymers.

P2860

Q26740303-29E4EEDB-85A1-453B-80AC-244076C73023 Q26752799-8D5A4E31-8531-4B13-B3BD-01E2F9F47387 Q26766832-2AD72051-43DC-42F2-9ACF-271C2CBF1914 Q26782794-B82D5E25-E246-4CFA-9DEF-8D27DBFA93E8 Q26825644-8C503F74-744E-4A79-B0B5-4841E1896C51 Q27681282-0AB459BB-89B9-4447-913B-E516A8009EAC Q34885269-AA17ED47-8D30-4A6C-BCBD-FD180E8E9C97 Q35309726-4AA897F3-C1DC-4889-8388-77DB4F816F26 Q35740280-8D19F8E5-F9D0-47DE-9211-78BACFF6529B Q35852997-2C37705C-DEB8-4AAD-988C-300E6586202B Q36020230-4EE97D59-D63C-4FB5-A0FC-BD39F3197C9C Q36285843-0230B9ED-20B1-4403-A428-C880CF785975 Q36579912-036C84B6-D034-4E09-BD86-092A664C8310 Q36619856-D68F99AB-3A79-4B9D-BAE3-DBBBC5C8ADBE Q37711632-EB3C2574-F977-4134-8E1F-2954A3F72AC1 Q38297362-9F9A7BF1-2645-4058-A050-2572CDCB768E Q38298067-C9EA7896-A4D2-4425-9320-D63206B47BD2 Q38488502-6BF4981C-1926-4AE9-A81B-7AF0DC23C8B5 Q38504825-F646A584-5900-411F-88CE-52026985CEC9 Q38791725-05E96D79-B589-42DB-AFC9-232E4BFEB110 Q38931171-1C5E15BF-7AC2-44E3-B59B-9101E326D3D8 Q38945150-36FF0E57-F4AF-436E-BC7C-6868A277D208 Q40464660-F17A52C4-D2BD-44BF-8B75-2D19D9D9BC98 Q41573492-570CD6AB-8B00-40B7-BF36-2F8A0F5F1649 Q41840024-D77DDC3A-237E-46C6-BACD-1B8289C602A1 Q42321077-263DB85B-5501-48DE-A038-B02D9A8CF3B6 Q47104247-B21DEDFB-527D-429F-920F-057DC71493B8 Q47109727-EB23625E-2468-4EB7-AFE8-DF37BA55EAA7 Q48354970-9ADFEF0F-63B5-413D-84D1-5734B9CACB22 Q50867707-A23417FD-7AA5-41CC-BE11-FB6FF9946D43 Q50954695-D095F18D-A95D-4C6D-85DA-12FD3133EA45 Q52312646-5AFE045D-EA12-46E0-89E4-7F89A93FC020 Q52673150-E4A853B6-4A89-4017-8860-315361CB1C20

P2860

Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor.

http://www.wikidata.org/entity/Q38309810

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Chemically modified DNA aptame ...... n with interleukin-6 receptor.

@en

type

label

Chemically modified DNA aptame ...... n with interleukin-6 receptor.

@en

prefLabel

Chemically modified DNA aptame ...... n with interleukin-6 receptor.

@en

P1433

Q38309810-C6A86C61-229C-4DEF-A630-00720BB0D6AA

P1476

Q38309810-938F28AE-3F5F-4D10-BB56-B5499703E701

P2093

Q38309810-0428B6B5-B5D7-4E26-9E14-69AA81272143

Q38309810-14D75EB4-5A66-4D36-A5A8-2FF4646CCEA5

Q38309810-15928F49-18C5-4A35-A9BB-A092D1898F88

Q38309810-25F2F91C-BE92-409F-BB49-F4A69AC7F255

Q38309810-408481EF-A4F5-4F61-B160-3A74151D337D

Q38309810-5F93D2A7-7EFF-453E-8784-41FC149CA212

Q38309810-61AD7927-0537-42DE-A6CB-C2A7C0D3A7C3

Q38309810-7D33C27A-B44B-4206-952C-82D6EC166C4E

Q38309810-A01839E1-F0F3-4836-B80F-7753A4BCC1CB

Q38309810-A2ACE944-5D57-4F3A-902D-FBF77670567E

P2860

Q38309810-01BBE1EE-D3A5-41FF-8B32-048F3BA77A41

Q38309810-02C22FED-B2A0-4815-94A9-865C912349D9

Q38309810-07FC170F-83CF-4075-A70D-B3A83F3A8A6F

Q38309810-091F2622-B14F-4EE8-837F-B53695A31213

Q38309810-0BA29FE6-71D2-4E28-8DB8-75B6EF38C248

Q38309810-1B97AF8C-9AFE-4110-8F31-08087D821E11

Q38309810-2FE6621E-6479-4529-BB70-B97333592A9A

Q38309810-32509B53-AE76-4466-AE4B-635B145FF1D0

Q38309810-367426AD-87EC-4551-A1DC-8855E639D186

Q38309810-3ED7803C-3636-4B1F-BF5F-0A26F7997B19

P304

Q38309810-2E1067F5-98CE-4ABE-B28B-A0B8D3C22078

P31

Q38309810-E7B04292-3126-4E58-99DB-FCA96BD6855D

P356

Q38309810-CB4F8FAD-ED5A-4C24-95F1-D632F8FD8027

P407

Q38309810-A0539F62-D02F-488B-AEFD-3F130218FE07

P433

Q38309810-358AB985-88D3-40F6-B2DD-FD3933165ED9

P478

Q38309810-5E4B57F2-FE4B-4AF3-87E0-058232BEFCC4

P577

Q38309810-78AAD01B-AE23-403C-A527-E643FF6495F2

P698

Q38309810-1564A10E-B689-4ACA-A274-5D3C7EFC6ED0

P921

Q38309810-6a294e9a-3113-4382-9640-da2b49a656b9

P932

Q38309810-F1DD6638-1186-4CD5-A52D-6FACF8A96513

P356

JBC.M113.532580

P1433

Journal of Biological Chemistry

P1476

Chemically modified DNA aptame ...... n with interleukin-6 receptor.

@en

P2093

Bharat Gawande

http://www.w3.org/2001/XMLSchema#string

Chi Zhang

http://www.w3.org/2001/XMLSchema#string

Daniel J Schneider

http://www.w3.org/2001/XMLSchema#string

Ikuo Murakami

http://www.w3.org/2001/XMLSchema#string

Jeffrey D Carter

http://www.w3.org/2001/XMLSchema#string

Masafumi Shibamori

http://www.w3.org/2001/XMLSchema#string

Masahiro Muraguchi

http://www.w3.org/2001/XMLSchema#string

Masao Hirota

http://www.w3.org/2001/XMLSchema#string

Michael Vrkljan

http://www.w3.org/2001/XMLSchema#string

Nebojsa Janjic

http://www.w3.org/2001/XMLSchema#string

P2860

Interleukin-6: a new therapeutic target

Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin

Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway

Soluble cytokine receptors are present in normal human urine

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets

Crystal Structure of Interleukin-6 in Complex with a Modified Nucleic Acid Ligand

Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase

In vitro selection of RNA molecules that bind specific ligands

A road map for those who don't know JAK-STAT

P304

8706-8719

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M113.532580

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

289

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24415766

http://www.w3.org/2001/XMLSchema#string

P921

P932

3961692

http://www.w3.org/2001/XMLSchema#string